Norovirus-derived peptide–HLA complex

The **Norovirus-derived peptide–HLA complex** refers to a molecular structure formed when a peptide derived from the norovirus (typically from viral proteins such as VP1 or NS6) is presented on the cell surface by a human leukocyte antigen (HLA) class I molecule. This complex is recognized by the T cell receptor (TCR) on cytotoxic CD8+ T cells, mediating immune targeting of norovirus-infected cells. Specific norovirus epitopes presented by HLA class I molecules (for example, TMFPHIIVDV presented by HLA-A*0201 or GRNTHNVHL presented by HLA-B*27:05) have been identified as crucial for the activation of antiviral T cell responses in humans[1][2][3]. These complexes are not drug targets per se but serve as important immunological targets for both vaccine design and cell-based therapies; their detection (using peptide–HLA tetramers) is a key biomarker in research for tracking and analyzing the immune response against norovirus infection[1][2][3]. There are currently no approved drugs that modulate these complexes directly.

Other names

Norovirus epitope–HLA complexNorovirus peptide–HLA complexNoV–HLA complex

Antigen presentation to T cell receptors on cytotoxic T lymphocytes